# Intermediate-Size Patient Population Expanded Access Program for Intravenous Difelikefalin

> **NCT05031546** · — · APPROVED_FOR_MARKETING · sponsor: **Cara Therapeutics, Inc.**

## Conditions studied

- Uremic Pruritus

## Interventions

- **DRUG:** Difelikefalin

## Key facts

- **NCT ID:** NCT05031546
- **Lead sponsor:** Cara Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2022-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05031546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05031546, "Intermediate-Size Patient Population Expanded Access Program for Intravenous Difelikefalin". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05031546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*